{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:00:04Z","timestamp":1776121204054,"version":"3.50.1"},"reference-count":175,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2017,3,4]]},"DOI":"10.1080\/17474086.2017.1283213","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T05:24:13Z","timestamp":1484630653000},"page":"217-228","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Emerging treatment approaches for myeloma-related bone disease"],"prefix":"10.1080","volume":"10","author":[{"given":"Maria","family":"Gavriatopoulou","sequence":"first","affiliation":[{"name":",","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":",","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":",","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":",","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,1,29]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.293"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.09.36"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602223340802"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.041131"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.204.1.9205246"},{"key":"e_1_3_2_9_1","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: pathophysiology and management","volume":"16","author":"Terpos E","year":"2005","unstructured":"Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol. 2005;16(8):1223\u20131231.","journal-title":"Ann Oncol"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2013.874943"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.06.029"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-013-9794-7"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0380"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030847"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.7901"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.11.008"},{"key":"e_1_3_2_17_1","first-page":"115","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"101","author":"Terpos E","year":"2016","unstructured":"Terpos E, Kleber M, Engelhardt M, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2016;101:115\u2013208.","journal-title":"Haematologica"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-392522"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bonekey.2015.113"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(11)70004-X"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-435750"},{"key":"e_1_3_2_22_1","unstructured":"A double-blind placebo-controlled randomized phase 2 study of BHQ880 an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb) in patients with untreated multiple myeloma and renal insufficiency. n d [cited 2015 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01337752"},{"key":"e_1_3_2_23_1","unstructured":"A phase Ib\/II multicenter dose-determination study with an adaptive randomized placebo-controlled double-blind phase II using various repeated IV doses of BHQ880 in combination with zoledronic acid in relapsed or refractory myeloma patients with prior n d. [cited 2015 Jan 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00741377"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70157-7"},{"issue":"1","key":"e_1_3_2_25_1","first-page":"30","article-title":"A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents","volume":"6","author":"Ria R","year":"2013","unstructured":"Ria R, Reale A, Moschetta M, et al. A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents. Int J Clin Exp Med. 2013;6(1):30\u201338.","journal-title":"Int J Clin Exp Med"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq259"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.10.019"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/16852"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12449"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712590902845610"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.085"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.09.002"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3527"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3534"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2269"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.8604"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5234"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2146"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.96"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7101"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/35083081"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/35077108"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2005-0220"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728220903025770"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22033"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-368472"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-191577"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2013.01.012"},{"key":"e_1_3_2_52_1","doi-asserted-by":"crossref","first-page":"Abstract 331","DOI":"10.1182\/blood.V120.21.331.331","article-title":"Early evidence of anabolic bone activity of BHQ880, a fully human anti-dkk1 neutralizing antibody: results of a phase 2 study in previously untreated patients with smoldering multiple myeloma at risk for progression","volume":"120","author":"Munshi NC","year":"2012","unstructured":"Munshi NC, Beck JT, Bensinger W, et al. Early evidence of anabolic bone activity of BHQ880, a fully human anti-dkk1 neutralizing antibody: results of a phase 2 study in previously untreated patients with smoldering multiple myeloma at risk for progression. Blood. 2012;120:Abstract 331. ASH, Atlanta, Georgia","journal-title":"Blood"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0049"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-077685"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.5.537"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.39.2.91"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06196.x"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27342"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.22"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2012.697154"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2005.02.005"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2004.05.023"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg599"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081206"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.182"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.135"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.307"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203345"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2092"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.173"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305224"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12079-009-0063-5"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147837"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.10219"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2015.12.014"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3893"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.08.014"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu425"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds068"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2614-0"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.4467"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/iep.12171"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25591"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.90"},{"key":"e_1_3_2_85_1","first-page":"181","article-title":"Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model","volume":"28","author":"Kyutoku M","year":"2011","unstructured":"Kyutoku M, Taniyama Y, Katsuragi N, et al. Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. Int J Mol Med. 2011;28:181\u2013186.","journal-title":"Int J Mol Med"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.49.29594"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.3109\/08977199509028966"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.1699"},{"key":"e_1_3_2_89_1","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1016\/S0021-9258(18)42930-4","article-title":"Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin","volume":"267","author":"Hashimoto M","year":"1992","unstructured":"Hashimoto M, Shoda A, Inoue S, et al. Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin. J Biol Chem. 1992;267:4999\u20135004.","journal-title":"J Biol Chem"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.01012.x"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2005.04.005"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10613"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-001-0544-2"},{"key":"e_1_3_2_94_1","first-page":"143","article-title":"Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells","volume":"20","author":"Gobbi G","year":"2002","unstructured":"Gobbi G, Sangiorgi L, Lenzi L, et al. Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol. 2002;20:143\u2013147.","journal-title":"Int J Oncol"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0070243"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0303-7207(01)00497-X"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911929107"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1992"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.738666"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.142"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.50"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12835"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081208"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2825356"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.015"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.05.012"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080324"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-1050-9_6"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1820"},{"issue":"309","key":"e_1_3_2_110_1","article-title":"Myeloma cells decrease ephb4 expression in osteoblasts: a novel mechanism for regulation of bone formation in multiple myeloma","volume":"22","author":"Bates AL","year":"2007","unstructured":"Bates AL, Mundy GR, Edwards CM. Myeloma cells decrease ephb4 expression in osteoblasts: a novel mechanism for regulation of bone formation in multiple myeloma. J Bone Miner Res. 2007;22:(S309)(abstract).","journal-title":"J Bone Miner Res"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.6.3511"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1089\/met.2007.0029"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2004.06.008"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20890"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.03.210"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2006.00164.x"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(03)00237-0"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-861483"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2097"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-330407"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/3.1.161"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708935200"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.12.037"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205205"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2012.09.008"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-396853"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.13.3.1759-1768.1993"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-346775"},{"issue":"1","key":"e_1_3_2_129_1","first-page":"S180","article-title":"The transcription repressor Gfi1 directly interacts with the Runx2 gene in osteoblast precursors to mediate repression by multiple myeloma cells via TNFalpha, leading to blocked osteoblast differentiation","volume":"26","author":"Jin SDS","year":"2011","unstructured":"Jin SDS, Sun Q, Sammut B, et al. The transcription repressor Gfi1 directly interacts with the Runx2 gene in osteoblast precursors to mediate repression by multiple myeloma cells via TNFalpha, leading to blocked osteoblast differentiation. J Bone Miner Res. 2011;26(S1):S180.","journal-title":"J Bone Miner Res"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.671"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2383"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04561.x"},{"key":"e_1_3_2_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12445"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500175049"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2004.11.015"},{"key":"e_1_3_2_136_1","unstructured":"Oyayobi B Williams PJ Pulkrabek D et al. In vivo osteoclastogenic effects of the CC chemokine macrophage inflammatory protein (MIP)-1\u03b1. Bone. 2001;27:S81."},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-006-9038-6"},{"key":"e_1_3_2_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.43"},{"key":"e_1_3_2_139_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043"},{"key":"e_1_3_2_140_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404228"},{"key":"e_1_3_2_141_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0753"},{"key":"e_1_3_2_142_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0201"},{"key":"e_1_3_2_143_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16198"},{"key":"e_1_3_2_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.05.098"},{"key":"e_1_3_2_145_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-70630-6_12"},{"key":"e_1_3_2_146_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21310"},{"key":"e_1_3_2_147_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174300"},{"key":"e_1_3_2_148_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06356.x"},{"key":"e_1_3_2_149_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00692.x"},{"key":"e_1_3_2_150_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06829.x"},{"key":"e_1_3_2_151_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031302"},{"key":"e_1_3_2_152_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28481"},{"key":"e_1_3_2_153_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01599.x"},{"key":"e_1_3_2_154_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.267"},{"key":"e_1_3_2_155_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3450"},{"key":"e_1_3_2_156_1","first-page":"129","article-title":"Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation","volume":"33","author":"Munemasa S","year":"2008","unstructured":"Munemasa S, Sakai A, Kuroda Y, et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol. 2008;33:129\u2013136.","journal-title":"Int J Oncol"},{"key":"e_1_3_2_157_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.174"},{"key":"e_1_3_2_158_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403890"},{"key":"e_1_3_2_159_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23577"},{"key":"e_1_3_2_160_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387365"},{"key":"e_1_3_2_161_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035857"},{"key":"e_1_3_2_162_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2010.11.010"},{"key":"e_1_3_2_163_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2012.108"},{"key":"e_1_3_2_164_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2258"},{"key":"e_1_3_2_165_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1483"},{"key":"e_1_3_2_166_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2452"},{"key":"e_1_3_2_167_1","doi-asserted-by":"crossref","first-page":"12950e12967","DOI":"10.18632\/oncotarget.2633","article-title":"LIGHT\/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease","volume":"5","author":"Brunetti G","year":"2014","unstructured":"Brunetti G, Rizzi R, Oranger A, et al. LIGHT\/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. Oncotarget. 2014;5:12950e12967.","journal-title":"Oncotarget"},{"key":"e_1_3_2_168_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-014-2163-7"},{"key":"e_1_3_2_169_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1703"},{"key":"e_1_3_2_170_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1803-3"},{"key":"e_1_3_2_171_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.37"},{"key":"e_1_3_2_172_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12436"},{"key":"e_1_3_2_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.02.012"},{"key":"e_1_3_2_174_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-246660"},{"key":"e_1_3_2_175_1","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.2000.0681"},{"key":"e_1_3_2_176_1","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783X-19-23"},{"key":"e_1_3_2_177_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.228"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2017.1283213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:17:31Z","timestamp":1772745451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2017.1283213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,29]]},"references-count":175,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3,4]]}},"alternative-id":["10.1080\/17474086.2017.1283213"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2017.1283213","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}